KFAS
PVLA icon

Keating Financial Advisory Services’s Palvella Therapeutics PVLA Stock Holding History

Keating Financial Advisory Services’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22K Buy
8
+7
+700% +$850 ﹤0.01% 2110
2026
Q1 		$125 Buy
+1
New +$104 ﹤0.01% 2398

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Keating Financial Advisory Services's PVLA Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Palvella Therapeutics (PVLA) stake by 700% in Q2 2026, buying an estimated $850 and bringing the position to 8 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Keating Financial Advisory Services first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Keating Financial Advisory Services held 8 shares of Palvella Therapeutics worth $1.22K as of Q2 2026.
  • Keating Financial Advisory Services bought 7 Palvella Therapeutics shares in Q2 2026, an estimated $850.
  • Palvella Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2110 holding.
  • Keating Financial Advisory Services first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.